Accelerating Medical Treatments for Serious Mental Illness
Signed: April 18, 2026
Published: April 22, 2026
Document Number: 2026-07907
đSummary
This executive order aims to speed up research, review, and access to certain psychedelic-based treatments (including ibogaine compounds) for serious mental illnesses, especially for patients who do not improve with standard therapies. It affects federal agencies (FDA, DEA, HHS, VA, and the Department of Justice), state governments running or developing psychedelic-treatment programs, researchers and clinicians, and eligible patientsâparticularly including veterans. It directs the FDA to prioritize review of qualifying psychedelic drugs by issuing National Priority Vouchers and instructs the FDA and DEA to create a workable path for patient access under the federal Right to Try law, including needed authorizations to handle Schedule I substances. It also requires HHS to dedicate at least $50 million from existing funds to partner with states, and tells HHS, FDA, and VA to expand clinical trial participation and share data to support faster evaluation and potential approval. Finally, it directs the Attorney General, working with HHS, to quickly review whether specific products that complete Phase 3 trials and later win FDA approval should be moved out of Schedule I as soon as practicable.
đźBusiness Impact
This order most directly impacts **biopharma/biotech developing psychedelic therapies**, **CROs and clinical trial sites**, **health systems/behavioral health clinics**, **compounding/manufacturing and controlled-substance logistics**, and **digital health/data vendors**âespecially those serving **veterans** and treatmentâresistant depression/substance use populations. It creates near-term opportunities via **faster FDA attention (priority vouchers), expanded âRight to Tryâ access pathways, and $50M in HHS/ARPAâH support for state programs**, but also raises compliance needs around **Schedule I handling (DEA registrations/authorizations), protocol and documentation standards for Right to Try, and HIPAA/Privacy Actâcompliant data sharing** with VA/HHS/FDA. Businesses should immediately **map which products qualify for Breakthrough Therapy + Phase 3 timelines**, **engage regulatory counsel to prepare DEA/FDA RightâtoâTry workflows**, and **pursue partnerships/grants with states and VA-affiliated trial networks** while strengthening **controlled-substance security, chain-of-custody, and realâworld evidence/data governance** capabilities.
Full Text
Due to aggressive automated scraping of FederalRegister.gov and eCFR.gov, programmatic access to these sites is limited to access to our extensive developer APIs. Please visit FederalRegister.gov API documentation or eCFR.gov API documentation to learn more about how to access the API.
Your request has been flagged as potentially automated. If you are human user receiving this message, please complete the CAPTCHA (bot test) below and click "Request Access". You may occassionally be asked to complete the CAPTCHA again, this is normal and part of our security measures.
An official website of the United States government.
If you experiencing issues with the CAPTCHA or want to request a wider IP range, you can use the "Site Help" button found in the lower, right of this page to make a request.